OVERVIEW

Beyond Borders in Relapsed/Refractory Multiple Myeloma (RRMM): Optimizing BCMA Bispecific and CD38-Based Combination Therapy is organized by Iridium Continuing Education, Global Education Group.

Release: August 31,2026
Expiration: August 31, 2027

Program Overview:
Beyond Borders in RRMM: Optimizing BCMA Bispecific and CD38-Based Combination Therapy is an enduring CME/CE webcast designed to improve clinician competence in the evidence-based integration of BCMA-targeted bispecific antibodies and CD38-based combination therapies for relapsed/refractory multiple myeloma (RRMM). Through expert faculty presentations and Conversational AI clinical simulations, the activity addresses gaps in treatment selection, risk stratification, toxicity management, step-up dosing, and sequencing strategies in real-world practice. Learners will engage in interactive, case-based education designed to strengthen clinical decision-making, shared decision-making, and safe implementation of emerging RRMM immunotherapy approaches.

Learning Objectives:
Upon completion of this activity, the participant should be able to:

Integrate emerging evidence on BCMA BsAb and CD38 antibody combination therapy into individualized RRMM treatment decisions
Apply cytogenetic risk stratification, prior therapy exposure assessment, and patient fitness criteria to guide individualized selection among BCMA BsAb combinations, CAR-T cell therapy, and antibody-drug conjugates in RRMM
Implement appropriate step-up dosing, toxicity mitigation, and sequencing strategies for BsAb-based therapies in RRMM